Fanbo Jing

620 total citations
33 papers, 489 citations indexed

About

Fanbo Jing is a scholar working on Molecular Biology, Oncology and Epidemiology. According to data from OpenAlex, Fanbo Jing has authored 33 papers receiving a total of 489 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 13 papers in Oncology and 6 papers in Epidemiology. Recurrent topics in Fanbo Jing's work include Peptidase Inhibition and Analysis (9 papers), Nanoparticle-Based Drug Delivery (5 papers) and Cancer-related gene regulation (4 papers). Fanbo Jing is often cited by papers focused on Peptidase Inhibition and Analysis (9 papers), Nanoparticle-Based Drug Delivery (5 papers) and Cancer-related gene regulation (4 papers). Fanbo Jing collaborates with scholars based in China and Japan. Fanbo Jing's co-authors include Qie Guo, Wenfang Xu, Hao Fang, Wen Xu, Jialin Sun, Haijun Qu, Guangwei Liu, Minyong Li, Haoyi Zheng and Jun Zhao and has published in prestigious journals such as BioMed Research International, Oncotarget and International Journal of Nanomedicine.

In The Last Decade

Fanbo Jing

33 papers receiving 481 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fanbo Jing China	13	274	102	63	62	59	33	489
Haiwei Xu China	12	266 1.0×	127 1.2×	46 0.7×	42 0.7×	76 1.3×	27	518
Rishi K. Gara India	12	323 1.2×	98 1.0×	65 1.0×	84 1.4×	80 1.4×	12	594
Vinod Balachandran India	12	315 1.1×	130 1.3×	71 1.1×	62 1.0×	48 0.8×	14	598
Samil Jung South Korea	17	497 1.8×	88 0.9×	66 1.0×	83 1.3×	63 1.1×	34	877
Akshaya Murugesan Finland	10	225 0.8×	56 0.5×	27 0.4×	47 0.8×	90 1.5×	35	477
Mehboob Hoque India	13	249 0.9×	52 0.5×	74 1.2×	44 0.7×	45 0.8×	42	633
Sonam Mittal India	14	406 1.5×	81 0.8×	45 0.7×	111 1.8×	53 0.9×	28	701
Aar Rafi Mahmud Bangladesh	4	230 0.8×	142 1.4×	50 0.8×	85 1.4×	50 0.8×	6	508
Marta Hałas‐Wiśniewska Poland	11	231 0.8×	76 0.7×	25 0.4×	60 1.0×	29 0.5×	32	466

Countries citing papers authored by Fanbo Jing

Since Specialization

Citations

This map shows the geographic impact of Fanbo Jing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fanbo Jing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fanbo Jing more than expected).

Fields of papers citing papers by Fanbo Jing

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fanbo Jing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fanbo Jing. The network helps show where Fanbo Jing may publish in the future.

Co-authorship network of co-authors of Fanbo Jing

This figure shows the co-authorship network connecting the top 25 collaborators of Fanbo Jing. A scholar is included among the top collaborators of Fanbo Jing based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fanbo Jing. Fanbo Jing is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Liang, Zhongqiang Li, Yuxin Chen, et al.. (2025). Design, synthesis, and anti-cancer evaluation of the novel conjugate of gemcitabine's ProTide prodrug based on CD13. Bioorganic Chemistry. 157. 108293–108293. 1 indexed citations

Liu, Yan, et al.. (2024). Research progress of novel anti-tumor drug formulations. Frontiers in Oncology. 14. 1507958–1507958. 1 indexed citations

Guo, Qie, et al.. (2023). Ubenimex suppresses glycolysis mediated by CD13/Hedgehog signaling to enhance the effect of cisplatin in liver cancer. Translational Cancer Research. 12(10). 2823–2836. 2 indexed citations

Qu, Haijun, et al.. (2022). Anti-inflammatory Mechanism of Action of Benzoylmesaconine in Lipopolysaccharide-Stimulated RAW264.7 Cells. Evidence-based Complementary and Alternative Medicine. 2022. 1–12. 12 indexed citations

Liu, Donghua, et al.. (2022). Risk Factors and Incidence of Malignancy After Kidney Transplant in Mainland China: A Single-Center Analysis. Experimental and Clinical Transplantation. 20(6). 558–563. 2 indexed citations

Guo, Qie, et al.. (2022). CD13 downregulation mediated by ubenimex inhibits autophagy to overcome 5-FU resistance by disturbing the EMP3/FAK/NF-κB pathway in gastric cancer cells. Translational Cancer Research. 11(8). 2487–2500. 5 indexed citations

Guo, Qie, et al.. (2022). SLC6A14 Depletion Contributes to Amino Acid Starvation to Suppress EMT‐Induced Metastasis in Gastric Cancer by Perturbing the PI3K/AKT/mTORC1 Pathway. BioMed Research International. 2022(1). 7850658–7850658. 7 indexed citations

Wang, Yongmei, Fanbo Jing, & Haibo Wang. (2022). Role of Exemestane in the Treatment of Estrogen-Receptor-Positive Breast Cancer: A Narrative Review of Recent Evidence. Advances in Therapy. 39(2). 862–891. 10 indexed citations

Guo, Qie, et al.. (2021). Ubenimex Suppresses the Ability of Migration and Invasion in Gastric Cancer Cells by Alleviating the Activity of the CD13/NAB1/MAPK Pathway. Cancer Management and Research. Volume 13. 4483–4495. 6 indexed citations

10.

Guo, Qie, et al.. (2021). Facing Cell Autophagy in Gastric Cancer – What Do We Know so Far?. International Journal of General Medicine. Volume 14. 1647–1659. 8 indexed citations

11.

Guo, Qie, Haijun Qu, Wen Xu, et al.. (2019). Ubenimex Reverses MDR in Gastric Cancer Cells by Activating Caspase-3-Mediated Apoptosis and Suppressing the Expression of Membrane Transport Proteins. BioMed Research International. 2019. 1–14. 17 indexed citations

12.

Li, Xiao, Fanbo Jing, Wen Xu, et al.. (2019). <p>Identifying risk factors for high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia</p>. Cancer Management and Research. Volume 11. 6265–6274. 20 indexed citations

13.

Zhao, Jun, et al.. (2019). Ursolic acid exhibits anti-inflammatory effects through blocking TLR4-MyD88 pathway mediated by autophagy. Cytokine. 123. 154726–154726. 59 indexed citations

14.

Li, Xiao, Xin Li, Wen Xu, et al.. (2018). Perfluorooctylbromide nanoparticles for ultrasound imaging and drug delivery. International Journal of Nanomedicine. Volume 13. 3053–3067. 32 indexed citations

15.

Sun, Jialin, Wen Xu, Junke Song, et al.. (2017). A Novel UPLC-MS/MS Method for the Determination of Salvianolic Acid A in Rat Urine, Feces, and Bile and its Application to Excretion Study. Current Pharmaceutical Analysis. 15(3). 266–272. 3 indexed citations

16.

Guo, Qie, Wen Xu, Jialin Sun, et al.. (2017). Ubenimex suppresses Pim-3 kinase expression by targeting CD13 to reverse MDR in HCC cells. Oncotarget. 8(42). 72652–72665. 24 indexed citations

17.

Jing, Fanbo, et al.. (2017). Docetaxel prodrug self-assembled nanosystem: Synthesis, formulation and cytotoxicity. Bioorganic & Medicinal Chemistry Letters. 28(4). 826–830. 24 indexed citations

18.

Luan, Yepeng, Fanbo Jing, Jian Zhang, et al.. (2012). Design, Synthesis, and Activity Evaluation of a New 5-fluorouracil Prodrug Containing an Asn-Gly-Arg(NO2)COOCH3 Tripeptide. Protein and Peptide Letters. 19(10). 1122–1131. 7 indexed citations

19.

Liu, Yu, Fanbo Jing, Yingying Xu, et al.. (2011). Design, synthesis and biological activity of thiazolidine-4-carboxylic acid derivatives as novel influenza neuraminidase inhibitors. Bioorganic & Medicinal Chemistry. 19(7). 2342–2348. 59 indexed citations

20.

Luan, Yepeng, Chunhua Ma, Xuejian Wang, et al.. (2010). LYP3, a New Bestatin Derivative for Aminopeptidase N Inhibition. Medicinal Chemistry. 7(1). 32–36. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact